| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S9481 R33341 |
Kilic (Primidone) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.81 [0.52;6.30] C excluded (control group) |
3/20 78/876 | 81 | 20 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9482 R33344 |
Kilic (Primidone) (Controls unexposed NOS) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: No |
1.65 [0.48;5.63] C excluded (control group) |
3/20 65,118/673,844 | 65,121 | 20 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9483 R33347 |
Kilic (Primidone) (Controls unexposed, sick) (Mixed indications), 2014 | Small for gestational age (birth weight <10% percentile for the gestational birth week) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.39 [0.41;4.76] C | 3/20 594/5,275 | 597 | 20 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9455 R33260 |
Burja (Primidone) (Controls unexposed, disease free), 2006 | Small for date (NOS) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, disease free excluded | Adjustment: No |
8.38 [0.16;432.63] C excluded (control group) |
1/1 23/211 | 24 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9456 R33265 |
Burja (Primidone) (Controls unexposed, sick), 2006 | Small for date (NOS) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 63.00 [0.51;7760.63] C | 1/1 1/32 | 2 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 4.47 [0.14;140.06] | 599 | 21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Primidone) (Controls unexposed, sick) (Mixed indications; 2: Primidone) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9455, 9481, 9482